{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:53:06Z","timestamp":1777866786255,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2003,5,1]],"date-time":"2003-05-01T00:00:00Z","timestamp":1051747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":6081,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2003,5]]},"DOI":"10.1093\/annonc\/mdg703","type":"journal-article","created":{"date-parts":[[2003,5,7]],"date-time":"2003-05-07T14:34:43Z","timestamp":1052318083000},"page":"i11-i16","source":"Crossref","is-referenced-by-count":41,"special_numbering":"S1","title":["Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin\u2019s lymphoma and Hodgkin\u2019s disease"],"prefix":"10.1016","volume":"14","author":[{"given":"M.S.","family":"Hertzberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Crombie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Benson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Taper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.F.","family":"Bradstock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdg703_bb0005","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1200\/JCO.1993.11.10.1846","article-title":"High-dose chemotherapy and ASCT for aggressive NHL","volume":"11","author":"Vose","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg703_bb0010","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1046\/j.1365-2141.1996.437976.x","article-title":"The role of intensive therapy and ASCT for chemotherapy sensitive relapsed and primary refractory NHL: identification of major prognostic groups","volume":"92","author":"Prince","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdg703_bb0015","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemo-poietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdg703_bb0020","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomized trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdg703_bb0025","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1200\/JCO.1992.10.6.936","article-title":"Treatment of patients with relapsed and resistant NHL using total body irradiation, etoposide and cyclophosphamide and ABMT","volume":"10","author":"Gulati","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg703_bb0030","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdg703_bb0035","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1200\/JCO.1989.7.2.179","article-title":"Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin\u2019s disease","volume":"7","author":"Jagannath","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg703_bb0040","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1200\/JCO.1993.11.8.1573","article-title":"EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin\u2019s lymphoma","volume":"11","author":"Wilson","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg703_bb0045","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood.V71.1.117.117","article-title":"Effective salvage therapy for lymphoma with cisplatin in combination with high dose Ara-C and dexamethasone (DHAP)","volume":"71","author":"Velasquez","year":"1988","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdg703_bb0050","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1200\/JCO.1994.12.6.1169","article-title":"ESHAP\u2014an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study","volume":"12","author":"Velasquez","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg703_bb0055","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1200\/JCO.1995.13.7.1734","article-title":"Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP","volume":"13","author":"Rodriguez","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg703_bb0060","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/sj.bmt.1701192","article-title":"Combination chemotherapy with mitoguanzone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphoma","volume":"21","author":"Aurlien","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1093\/annonc\/mdg703_bb0065","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/sj.bmt.1701592","article-title":"Ifosfamide and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma","volume":"23","author":"Mayer","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1093\/annonc\/mdg703_bb0070","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/sj.bmt.1701985","article-title":"Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin\u2019s lymphoma and Hodgkin\u2019s disease","volume":"24","author":"McQuaker","year":"1999","journal-title":"Bone Marrow Transplant"},{"issue":"3 Suppl 6","key":"10.1093\/annonc\/mdg703_bb0075","first-page":"27","article-title":"Ifosfamide for the treatment of non-Hodgkin\u2019s lymphoma","volume":"23","author":"Pohlman","year":"1996","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdg703_bb0080","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1200\/JCO.1999.17.12.3776","article-title":"Ifosfamide, carboplatin and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin\u2019s lymphoma","volume":"17","author":"Moskowitz","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg703_bb0085","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1182\/blood.V96.7.2399","article-title":"High-dose chemoradio-therapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin\u2019s lymphoma: an intention-to-treat analysis","volume":"96","author":"Kewalramani","year":"2000","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdg703_bb0090","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V97.3.616","article-title":"A two-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin\u2019s disease: analysis by intent to treat and development of a prognostic model","volume":"97","author":"Moskowitz","year":"2001","journal-title":"Blood"},{"issue":"Suppl","key":"10.1093\/annonc\/mdg703_bb0095","first-page":"56","article-title":"Rituximab and ifosfamide, mitoxantrone, etoposide (RIME) with Neupogen support for B-cell non-Hodgkin\u2019s lymphoma prior to high-dose chemotherapy with autologous haematopoietic transplant","volume":"64","author":"Joyce","year":"2001","journal-title":"Eur J Haematol"},{"key":"10.1093\/annonc\/mdg703_bb0100","first-page":"1459a","article-title":"Rituximab significantly increases the complete remission rate in patients with relapsed or primary refractory DLBCL receiving ICE as second-line therapy (SLT)","volume":"98","author":"Kewalramani","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdg703_bb0105","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/sj.bmt.1700963","article-title":"High dose therapy and ASCT for patients with HD in first relapse after chemotherapy: results from the EBMT","volume":"20","author":"Sweetenham","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1093\/annonc\/mdg703_bb0110","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1200\/JCO.1995.13.2.323","article-title":"Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem cell rescue: toxicity profile","volume":"13","author":"Fields","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg703_bb0115","first-page":"33","article-title":"Dose-intensive ifosfamide for the treatment of non-Hodgkin\u2019s lymphoma","volume":"23","author":"Vose","year":"1996","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdg703_bb0120","first-page":"175","article-title":"Ifosfamide by continuous infusion to prevent encephalopathy","volume":"333","author":"Cerny","year":"1989","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdg703_bb0125","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2125.1991.tb03860.x","article-title":"The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients","volume":"31","author":"Lewis","year":"1991","journal-title":"Br J Clin Pharmacol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419473699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419473699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/14\/suppl_1\/i11\/398474\/mdg703.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T11:47:40Z","timestamp":1582199260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419473699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5]]},"references-count":25,"alternative-id":["S0923753419473699"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdg703","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2003,5]]}}}